Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) – Pipeline Review, H2 2016’, provides in depth analysis on Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted pipeline therapeutics.

The report provides comprehensive information on the Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99)

The report reviews Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics and enlists all their major and minor projects

The report assesses Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Advinus Therapeutics Ltd

Johnson & Johnson

MAKScientific, LLC

Midatech Pharma US Inc.

Takeda Pharmaceutical Company Limited

Zynerba Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) Overview 7

Therapeutics Development 8

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Products under Development by Stage of Development 8

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Products under Development by Therapy Area 9

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Products under Development by Indication 10

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Products under Development by Companies 13

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Products under Development by Universities/Institutes 15

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Companies Involved in Therapeutics Development 22

Advinus Therapeutics Ltd 22

Johnson & Johnson 23

MAKScientific, LLC 24

Midatech Pharma US Inc. 25

Takeda Pharmaceutical Company Limited 26

Zynerba Pharmaceuticals, Inc. 27

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Drug Profiles 28

AM-3506 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

AM-5206 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

IPI-940 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

JNJ-40413269 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

KRN-5500 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecule to Inhibit FAAH for Pain - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules to Inhibit COX and FAAH for Oncology, Immunology and CNS Disorders - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

URB-694 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

URB-937 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ZYN-002 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Dormant Projects 43

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Discontinued Products 45

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC

3.5.1.99) - Featured News & Press Releases 46

Sep 06, 2016: Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of Osteoarthritis 46

Aug 01, 2016: Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures 46

Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures 47

Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid 48

Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome 49

Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial 49

Oct 20, 2015: Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel 50

Jun 16, 2014: DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma 50

Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA 51

Nov 29, 2012: Dara BioSciences Submits Orphan Drug Application For KRN5500 To FDA 52

May 09, 2012: Dara To Advance Development Of KRN5500 For Treatment Of Cancer And Neuropathic Pain 52

Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients With Cancer 53

Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit 54

Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced Neuropathic Pain In Patients With Cancer 55

Jun 01, 2011: Infinity To Provide Update On IPI-940 55

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Advinus Therapeutics Ltd, H2 2016 22

Pipeline by Johnson & Johnson, H2 2016 23

Pipeline by MAKScientific, LLC, H2 2016 24

Pipeline by Midatech Pharma US Inc., H2 2016 25

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 26

Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 27

Dormant Projects, H2 2016 43

Dormant Projects (Contd..1), H2 2016 44

Discontinued Products, H2 2016 45

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports